A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

NCT07503873 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Ublituximab
DRUG: Ublituximab
DEVICE: AI Device

Sponsor

TG Therapeutics, Inc.